|
What does the ?MSD? means in the ?The Merck Manual of Medical Iformation? b
2008-11-19 20:28:00 MSD simply stands for Merck, Sharp & Dohm.
Vioxx Lawsuit Loan and Merck Class Action Lawsuit Funding
2008-09-16 19:39:00 If you are involved in a lawsuit against Merck for the whole Vioxx mess which has been going on over the last few years, there is a high likelihood that you can receive a loan on your lawsuit. How does lawsuit funding work on a Vioxx case? It?s very simple. You are part of a lawsuit against ...
RANBAXY INKS DRUG DEALS WITH MERCK
2008-05-15 12:12:00 Source: Times of India: 13th May; 2008(Tuesday) New Delhi: Ranbaxy has signed a collaboration agreement with US-based Merck for drug discovery and clinical development in anti-infective drugs.Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates , Ranbaxy will carry out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates after that.Ranbaxy CEO and MD, Malvinder M Singh told TOI: The agreement has already been signed and returns will start flowing to the company from this (second) quarter it-self?. He, however, didn?t provide details of revenues expected from the deal this year.Ranbaxy will be paid an undisclosed sum, with potential to receive payments over $100 million (per drug) associated with achievement of various R& D regulatory approval for each target included in the collaboration. Ranbaxy will also receive signifi...
FDA report shows problems at Merck vaccine plant
2008-05-01 19:58:00 FDA report shows problems at Merck vaccine plantBy Karl Stark Inquirer Staff WriterFederal inspectors documented unwanted "fibers" on the stoppers of vaccine vials at Merck & Co. Inc.'s vast vaccine plant in Montgomery County. They also found instances of contaminated children's vaccines and complaints that were not always investigated at the West Point plant.Inspectors from the U.S. Food and Drug Administration spent 30 days at the plant between November and January and cited 49 areas of concern, including a failure to follow good manufacturing practices.The findings are detailed in an unpublished 21-page FDA report obtained by The Inquirer under the federal Freedom of Information Act.Independent experts who reviewed the report say it documents serious concerns in one of the country's premier vaccine plants. They suggested the problems could be a symptom of Merck's cost cutting in the face of rapid growth of its vaccine business."I would fault the management for not providing e...
U.S. STOCKS - Market falls; Merck hits drug sector
2008-04-29 20:00:00 NEW YORK (Reuters) - U.S. stocks declined on Tuesday as shares of Merck & Co Inc, a Dow component, hit the drug sector, while investors had second thoughts about consumer confidence data, viewing it as negative for the economy's longer-term outlo2 Vote(s)
By: Market Buzz
FDA Denies Approval for Merck Drug
2008-04-29 01:04:00 The FDA denied approval for Merck's Cordaptive cholesterol drug, issuing a "not approvable" letter for the potential blockbuster. Merck reaffirmed its 2008 financial guidance despite the setback.
By: mini wisdom
Vioxx Study Used Ghostwriters paid by Merck?
2008-04-20 04:49:00 So you thought all those Vioxx studies in medical journals were independent, hands-off affairs? Not necesssarily. An examination of medical journal articles about Vioxx and court documents from Vioxx lawsuits found that Merck employees or ghostwriters were frequently involved in various articles, but the primary authors were often academics who actually had little to do ...
Pfizer Lagging Behind Merck in Developing Rimonabant Acomplia?s Competitor
2008-03-23 11:53:00 While Merck is wrapping up a series of clinical trials of diet drug Taranabant, which it expects to submit for FDA approval later this year, Pfizer has just launched a new Phase III trial of its diet drug CP-945,598, suggesting it may be considerably further away from being brought to market. Merck has two Phase III ...
Deadline In Merck Vioxx Settlement (CNNMoney.com)
2008-03-03 04:41:00 A key deadline in Merck & Co.'s (MRK) proposed $4.85 billion settlement of Vioxx product liability litigation comes Saturday, Mar. 8. If at least 85% of certain groups of plaintiffs - such as those who alleged Vioxx caused heart attacks - enroll in the settlement by then, Merck is expected to begin the process of making payments. Nearly 60,000 claims have been filed against Merck over Vioxx, the pain drug it pulled from the market in 2004 after a study linked it to higher risk of heart attack and stroke. The proposed settlement was announced in November. (CNNMoney.com) see also Killer VIOXX's Restorative Justice and Big Pharma and Grannies Special Tea http://pages.quicksilver.-net.nz/blair/media/vioxx1.htm -- Blair Anderson ?(?¿?)?Soci-al Ecologist 'at large'http://mildgreens.blo-gspot.comhttp://blairformayor.b-logspot.com http://blair4mayor.comph (643) 389 4065 cell 027 265 7219
Investing in Biotechnology: One Market Is Always a Bull Market
2008-02-21 20:37:00 It?s getting tougher and tougher to find safety. The tech sector is getting hit. Formerly high flying overseas are giving back some of their handsome gains. Even with oil prices hitting $100 a barrel again yesterday, the entire oil sector is off about 10% for the year. The bears have had their way. And, frankly, there ...
By: Jutia Group
Vytorin Worries Look Overdone in Shares of Merck, Schering
2008-02-04 19:36:00 The drug sector has been a tough place to invest in recent years as the FDA has become more and more strict, not only in approving new drugs but also with respect to labeling requirements for existing ones.Last year, new warning labels essentially crippled the anemia drug franchise at Amgen (AMGN), and a recently released study for Vytorin, a cholesterol drug from Merck (MRK) and Schering Plough (SGP), has investors worried. The market has slammed the two stocks, after study results showed that Vytorin (a combination drug composed of Zocor and Zetia) was no more effective than Merck’s Zocor in reducing the risk of heart disease. This is important because Zocor is available in generic form, while Vytorin is a new, more expensive medication.Zetia and Vytorin, both products of a cholesterol joint venture between Merck and Schering, netted the two companies about $5 billion of revenue in 2007, but that business is coming to question. If Vytorin is not as helpful as the companies have ...
Merck & Co. Inc. (MRK) Beats the Street
2008-01-30 13:33:00 -- Company Announces Full-Year 2007 Non-GAAP EPS of $3.20 and Fourth-Quarter Non-GAAP EPS of $0.80, Excluding Certain Previously Disclosed Items; Full-Year GAAP EPS of $1.49 and Fourth-Quarter GAAP... Continued on JimCramerBlog.com
By: Jim Cramer Blog
GTx and Merck Collaborate on New SARMs Muscle-building Drug, Ostarine!
2008-01-16 21:20:00 GTx, Inc. and Merck & Co., Inc. Enter Global Strategic Collaboration for the Development of SARMs, a Novel Investigational Class of Drugs to Treat Muscle Loss and other Musculoskeletal ConditionsGTx, Inc. (NASDAQ: GTXI) and Merck & Co., Inc. (NYSE: MRK) announced an agreement providing for a research and development and global strategic collaboration for selective androgen receptor modulators (SARMs), a new class of drugs with the potential to treat age-related muscle loss (sarcopenia) as well as other musculoskeletal conditions. This collaboration includes GTx's lead SARM candidate, OstarineTM, which is currently being evaluated in a Phase II clinical trial for the treatment of muscle loss in patients with cancer, and establishes a broad SARM collaboration under which GTx and Merck will pool their programs and partner to discover, develop, and commercialize current as well as future SARM molecules. As part of this global agreement, Merck will be responsible for all future ...
The Merck/Merial Manual for Pet Health: The complete pet health resource fo
2007-12-27 12:05:00 Used Price: $12.30 (component/option,com_apf_bridg-e/Itemid,32/query,myOperation::-Used--ItemId::0911910999/) Third Party New Price: $13.77 (component/option,com_apf_bridg-e/Itemid,32/query,myOperation::-New--ItemId::0911910999/) This item ships for FREE...
Watch those vaccine recalls i.e. Merck
2007-12-13 05:49:00 Now the voluntary Merck Hib vaccine was recalled. Now we should get inoculated for the influenza. Both of these are very true. It’s hard to keep in touch with the latest health care trends. Imprintitems.com offers the very safest “vaccine”: our syringe-shaped ballpoint pen imprinted with your hospital or clinic logo! Maybe these could be used ...
Merck?s AIDS Vaccine Study Had To Stop
2007-12-12 06:48:00 Merck’s two international experimental trials for an AIDS vaccine which began in December 2004 were stopped after researchers realized that the vaccine did not prevent infection with the AIDS virus, in fact, there was a surge in infection among vaccinated volunteers. The Merck vaccine trials were conducted in 15 cities in the United States, including ...
Nicholas in research deal with Merck
2007-11-20 00:49:00 Mumbai, Nov. 19 Drug-maker Nicholas Piramal India Ltd (NPIL) has forged a drug-development deal with Merck & Co Inc to discover and develop cancer drugs for two targets selected and provided by Merck. This is NPIL's second ... 2 Vote(s)
By: Market Buzz
Merck HIV Vaccine Trial Kills Participants: Could This Have Been Avoided?
2007-11-18 18:37:00 by TK Kenyon. "Recently, the Merck pharmaceutical company reported that its experimental HIV vaccine raised the rate of HIV infection among people who got the trial vaccine. The saddest part is that this is not surprising."
Job Vacancy at PT Merck
2007-11-16 16:00:00 PT. Merck Tbk, A German based company leading in pharmaceutical and chemical business in Indonesia, is opening opportunity for energetic and motivated professional with high level of commitment, competence and dedication to the benefit of customer, to fill in the following positions: area manager, product manager, training manager
By: Lowongan Kerja
Merck Agreement to Resolve U.S. VIOXX® Product Liability Lawsuits
2007-11-14 16:43:00 WHITEHOUSE STATION, N.J., Nov. 9, 2007 - Merck & Co., Inc. announced that it has entered into an agreement with the law firms that comprise the executive committee of the Plaintiffs' Steering Committee of the federal multidistrict VIOXX litigation as well as representatives of plaintiffs' counsel in state coordinated proceedings to resolve state and federal myocardial infarction (MI) and
Merck tells AIDS vaccine volunteers who got jab
(Reuters)
2007-11-14 00:00:00 ef="http://us.rd.yahoo.com/dail-ynews/rss/topstories/*http://ne-ws.yahoo.com/s/nm/20071113/ts_n-m/aids_vaccine_merck_dc"><i-mg src="http://d.yimg.com/us.yimg.-com/p/nm/20071114/2007_11_13t17-4355_450x335_us_aids_vaccine_me-rck.jpg?x=130&y=96&sig=-qLfwKY2uLtPUaJ2y1CCshQ--" align="left" height="96" width="130" alt="A general view shows the Merck facility in Rahway, New Jersey November 28, 2005. Thousands of people who volunteered to test an experimental AIDS vaccine that may have actually raised the risk of infection will be told if they got the actual shot, researchers said on Tuesday. (Jeff Zelevansky/Reuters)" border="0" /></a>Reuters - Thousands of people who volunteered to test an experimental AIDS vaccine that may have actually raised the risk of infection will be told if they got the actual shot, researchers said on Tuesday.</p>
Merck HIV Vaccine Increases Risk of HIV Infection
2007-11-10 23:54:00 Merck has been testing a candidate HIV vaccine in two large phase II clinical trials; the STEP study in North and South America, the Caribbean and Australia, and a parallel study called Phambili in South Africa. STEP was a multi-center, randomized, double-blind, placebo-controlled phase II test-of-concept clinical trial. Started in December 2004, enrollment in the ...
By: Highlight HEALTH
Merck to Pay $4.85B Vioxx Settlement
2007-11-09 17:29:00 TRENTON, N.J. (AP) — Merck & Co. said Friday it will pay $4.85 billion to end thousands of lawsuits over its painkiller Vioxx in what is believed to be the largest drug settlement ever.
By: Latest News
Merck Vioxx Settlement, to pay $4.85 Billion
2007-11-09 16:53:00 Merck Vioxx Settlement, to pay $4.85 Billion? Merck has agreed to pay an astounding amount of money to help settle lawsuits against the company. The lawsuit’s claim that the company’s painkiller drug Vioxx has caused strokes and heart attacks and 1000’s of people. The Merck Vioxx settlement is a move in the right direction for the ...
By: TheNewsLeak
Merck settles thousands of Vioxx suits
2007-11-09 14:28:00 MainCompany News Economy International News CEOs and CFOs in the News Media Biz Blog Fun Money Mergers and acquisitions Biggest deals YTD Corrections Financial News in Brief Main My Portfolio Stock Market News Indexes Pre-Market Stock Trades 24-hour
By: Get rich
Merck settles thousands of Vioxx suits
2007-11-09 14:28:00 MainCompany News Economy International News CEOs and CFOs in the News Media Biz Blog Fun Money Mergers and acquisitions Biggest deals YTD Corrections Financial News in Brief Main My Portfolio Stock Market News Indexes Pre-Market Stock Trades 24-hour
By: Get rich
Merck & Co. Inc. (MRK) Shares Likely to Rise: Barron's
2007-10-29 05:05:00 Merck & Co. Inc. (NYSE:MRK - News) shares could rise to $70 by 2010 if the drugmaker continues to deliver on its promise of double-digit earnings growth, Barron's said in its October 29 edition.Merck's earnings could hit $4 per share by 2010, the magazine said. It added that Morgan Stanley analyst Jami Rubin, who rates Merck shares overweight, thinks it might reach that level a year sooner.Applying its current multiple of 17.5 times prospective earnings to $4 a share would put the stock at $70, a 23 percent premium to its current share price of about $57, the magazine said. var dc_UnitID = 14; var dc_PublisherID = 18712; var dc_AdLinkColor = 'blue'; var dc_isBoldActive= 'no'; var dc_adprod='ADL'; ;
By: Jim Cramer Blog
ROUNDUP Merck KGaA Q3 core EPS soars, but lack of guidance on LCD ops weigh
2007-10-24 12:11:00 Darmstadt, Germany, Oct. 24, 2007 (Thomson Financial delivered by Newstex) — Merck (NYSE:MRK) KGaA said core EPS rose to 1.41 eur in the third quarter, beating expectations on the back of cost-cutting initiatives, but the company disappointed the market by failing to issue fresh guidance for its key liquid crystals unit. Core ...
By: Loan news blog
Merck to Report Results for Acomplia Rival ,Taranabant
2007-10-17 00:16:00 On Oct. 24th, Merck to Report Results for Acomplia Rival ,Taranabant At reunion ofThe Obesity Society’s annual scientific,which will be in New Orleans ,Merck is planning to deliver on Wednesday, October 24th the first official report about the results of trials of its new diet drug Taranabant which works by blocking ...
The Merck Veterinary Manual (Hardcover)
2007-09-14 18:35:00 The ninth edition was increased by 400 pages, and includes additional information on the news and being born diseases of animals, chapters widened on the urgency and critical care, much of chapters additional and revised of other.There is no comparable text which covers the same range, the number of species and the diversity of the topics matter than the Merck veterinary handbook. The hundreds of thousands of veterinary surgeons in the whole world were based on its exactitude and relevance during 50 years.The fiftieth edition of birthday of the resource of confidence in veterinary medicine was intensively revised and updated and includes last the discoveries, made, and practical at the management of the health of the animals.Buy Now...
Merck (MRK) Shares Rise Sharply
2007-09-11 16:51:00 Shares of German drugmaker Merck KGaA climbed sharply Tuesday after the company released successful new study results for its cancer drug Erbitux. Shares of biotechnology company ImClone, which developed the drug, soared nearly 24 percent in the U.S.Merck shares rose more than 5.7 percent at 97.56 euros ($134.52) in Frankfurt trading. ImClone Systems Inc., from which Merck bought the Erbitux licensing rights for outside the U.S. and Canada from in 1998, jumped 21 percent to $45.93, up $8.Merck said the phase III study, carried out on patients with advanced non-small cell lung cancer, showed that when Erbitux was combined with chemotherapy, it led to increased overall survival rates compared with when chemotherapy was used alone.Erbitux is already among Darmstadt-based Merck's top-selling products, and the study results appeared to strengthen its prospects."Non-small cell lung cancer that has spread from the primary site is extremely difficult to treat so we are delighted with these...
By: Jim Cramer Blog
Top Marketeer Returns to Merck to Promote Diet Drug Acomplia Competitor
2007-08-15 11:21:00 In the latest sign that things are going will with Merck?s development of a competitor to diet drug Acomplia (rimonabant), the pharmaceutical giant is bringing back Len Tacconi to serve as global brand leader for its weight-loss drug taranabant. Tacconi, who left Merck less than a year ago to become president of Discovery Health, spent a ...
Top Marketeer Returns to Merck to Promote Diet Drug Acomplia Competitor
2007-08-05 19:11:00 In the latest sign that things are going will with Merck’s development of a competitor to diet drug Acomplia (rimonabant), the pharmaceutical giant is bringing back Len Tacconi to serve as global brand leader for its weight-loss drug taranabant. Tacconi, who left Merck less than a year ago to become president of Discovery Health, spent a ...
Old medicine advertising - 7 - Merck
2007-07-22 13:00:00 Old medicine advertising (circa 1934?1940) of Merck Laboratory Ephetonina Eupaco Ultracarbon © Ira O'Neill on Bizarre Brazil, 2007. | Permalink See more posts in the category Advertising.
By: Bizarre Brazil
Merck and Ariad are working for new cancer drug
2007-07-14 06:02:00 It appears pharmaceutical giant Merck is wanting to get a larger piece of the cancer drug pie. The company iaspartnering with Ariad Pharmaceuticals to develop a new cancer treatment (in an experimental stage) with the potential to make the smaller Ariad over a billion greenbacks. Genentech’s Avastin has been selling like hotcakes lately, and the world ...
By: cancer war
Mylan acquires Merck’s unit
2007-05-14 01:36:00 AHMEDABAD:Mylan Laboratories Inc of US may have bagged Merck KGaA’s global genericsbusiness with its winning bid of euro 4.
Mylan to buy Merck Generics Unit
2007-05-13 13:32:00 Mylan Laboratories Inc. agreed to buy Merck KGaA's generic-drug unit for 4.9 billion euros ($6.7 billion) in cash to become the world's third-largest maker of generics.The acquisition will create a company with 2006 sales of about $4.2 billion. Mylan has arranged debt financing from Merrill Lynch & Co., Citigroup Inc. and Goldman Sachs Group, Inc. Mylan beat a rival bid by Teva, according to several people familiar with the transaction. Darmstadt, Germany-based Merck is selling the unit to pay down debt for its $13.7 billion acquisition of Serono SA. The purchase, the biggest in generics since Teva Pharmaceutical Industries Ltd.'s $7.6 billion takeover of U.S.- based Ivax Corp. in January 2006, brings to an end a four-month battle for the world's fourth-largest maker of generics. The price Mylan is paying is more than five times its own sales in the year ended March 2007 of $1.26 billion and more than its own market capitalization of $5.39 billion. The acquisition comes almos...
Merck Selling Generics Unit for $6.6B
2007-05-13 12:49:00 BERLIN -- German drug maker Merck KGaA announced Sunday that it is selling its generic drug business to Mylan Laboratories Inc. of the U.S. for euro4.
By: Get rich
Merck says FDA rejects Arcoxia arthritis drug
2007-05-08 08:03:00 NEW YORK, April 27 (Reuters) - Merck & Co. said on Friday that U.S. regulators have rejected its experimental arthritis drug Arcoxia, the drugmaker's follow-up to Vioxx, saying it could not be approved without new supportive data. Wall Street had expected the negative decision by the U.S. Food and Drug Administration after an advisory panel to the agency recommended Arcoxia not be approved earlier this month. Merck had been awaiting approval since December 2003 for the oral medicine, which is already sold in more than 60 other countri
Banking on Merck Stock (MRK)
2007-04-13 18:38:00 With the recent momentum in Merck I decided to pick up shares in the stock about a week ago and follow the recommendation warning of an imminent move to come. Merck & Co. shares jumped 7%, hitting a 52-week high Friday, after the company raised its earnings outlook and said a federal judge ...
By: Jutia Group
Merck Does Investors a Favor
2007-04-13 13:37:00 Shareholders in Merck (MRK) must be breathing a sigh of relief. An FDA panel voted 20-1 against approving Arcoxia, the company's experimental arthritis pain killer, but the stock rallied $1.50 in after-hours trading Thursday night. Why such enthusiasm? Merck just...
Merck Does Investors a Favor
2007-04-13 13:35:00 Shareholders in Merck (MRK) must be breathing a sigh of relief. An FDA panel voted 20-1 against approving Arcoxia, the company's experimental arthritis pain killer, but the stock rallied $1.50 in after-hours trading Thursday night. Why such enthusiasm? Merck just happened to announce an increase in earnings guidance for 2007 right after news of the FDA committee's decision hit the wires.While many companies fail when it comes to looking out for investors, Merck deserves kudos for the timing of this announcement. An increase in 2007 guidance to $2.80 per share, versus current consensus estimates of $2.65 is more than enough to reverse the stock's direction short term. Had the company waited until later in the month to announce the profit projections, the stock likely would have just recouped the losses suffered due to the FDA decision. Now, investors get a higher stock price despite the overwhelming angst over Arcoxia.Now, one could argue that Arcoxia was not expected to be approv...
Coley pharma licenses vaccine to merck
2007-04-13 10:04:00 Coley Pharmaceutical Group Inc. has licensed some vaccine technology to Merck & Co. Inc. in a deal potentially worth more than $37 million. (Source: bizjournals.com Health Care:Pharmaceuticals headlines) More: continued here
Merck to pay as much as $37m for product that improves vaccines
2007-04-13 09:04:00 Merck & Co. has agreed to pay up to $37 million for the rights to incorporate a Massachusetts drug maker’s vaccine adjuvant into vaccine candidates aimed at treating Alzheimer’s disease and a number of infectious diseases. (Source: bizjournals.com Health Care:Pharmaceuticals headlines) More: continued here
Merck & Co. (MRK): Let?s roll the dice and play a lil? Monopoly
2007-04-05 16:46:00 On March 22, 2007 I posted on the possibility of a surge in Merck stock. Technically we are not quite there yet, but shares are starting to move. It has climbed over a dollar since I mentioned it about two weeks ago. Does this make the stock expensive? Not at all. Shares are still ...
By: Jutia Group
Merck Wins FDA’s OK for Diabetes Pill (AP)
2007-04-01 00:00:00 A 2-in-1 medicine to treat diabetes has won federal approval, Merck & Co. Inc. said Saturday. The tablet, called Janumet, combines a proprietary Merck drug with the older diabetes drug metformin.
By: Commodity Wealth
Merck Wins FDA’s OK for Diabetes Pill (AP)
2007-04-01 00:00:00 A 2-in-1 medicine to treat diabetes has won federal approval, Merck & Co. Inc. said Saturday. The tablet, called Janumet, combines a proprietary Merck drug with the older diabetes drug metformin.
By: Commodity Wealth
Cdc finalizes advisory panel recommendations for gardasil®, merck?s cervica
2007-03-27 05:03:00 The U.S. Centers for Disease Control and Prevention (CDC) has adopted the unanimous recommendation of its Advisory Committee on Immunization Practices (ACIP) for the use of GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, Recombinant Vaccine] in girls and women ages 11 through 26. [click link for full article] (Source: Health News from ...
Merck KGaA Announces Serono Preliminary Figures for 2006 - Drug Newswire (p
2007-03-23 11:55:00 Merck KGaA Announces Serono Preliminary Figures for 2006Drug Newswire (press release), CT - 1 hour agoBearer shares of Merck Serono SA, the holding company, are traded on the virt-x (SEO) and its American Depositary Shares are traded on the New York Stock … Source: Internet-Marketing - Google News
By: AllToSearch
Is Merck & Co. (MRK) setting up for a big rally?
2007-03-22 14:27:00 Merck & Co., Inc. is a research- driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health, directly and through its joint ventures. The Company sells its products primarily to drug wholesalers and retailers, hospitals, clinics, government agencies and managed health care providers such as ...
By: Jutia Group
|
|
 |
|
 |
